肾结石相关经济毒性可致推荐治疗延迟及应对机制
一项基于ResearchMatch的全国横断面调查纳入945例肾结石患者,以COST-FACIT评分<21定义经济毒性,发现21.6%存在疾病相关经济毒性。经济毒性组更常延迟推荐的药物或手术治疗,且多因费用问题不遵循饮食建议;多因素分析显示COST-FACIT评分越高(经济负担越低)延迟治疗 odds 越低(OR 0.89,95%CI 0.87-0.92;P<.001)。
要点
- 肾结石患者中21.6%存在疾病相关经济毒性(COST≤20)。
- 经济毒性组延迟药物治疗比例28.3% vs 3.8%(P<.001)。
- 经济毒性组延迟手术治疗比例22.4% vs 3.4%(P<.001)。
核心结论
- 肾结石合并经济毒性的患者更可能延迟推荐的药物和手术治疗。
- 费用顾虑是患者不遵循药物、手术或饮食建议的常见原因。
研究设计与样本
- 全国横断面调查,纳入ResearchMatch注册的945例成人肾结石患者。
- 以COST-FACIT评分<21(即COST≤20)定义肾结石相关经济毒性。
主要发现
- 945例受访者中205例(21.6%)报告疾病相关经济毒性(COST≤20)。
- 经济毒性组延迟推荐药物治疗的比例为28.3%,非经济毒性组为3.8%(P<.001)。
- 经济毒性组延迟推荐手术治疗的比例为22.4%,非经济毒性组为3.4%(P<.001)。
- 经济毒性组更常将费用顾虑列为遵循营养建议的障碍。
- 多因素分析控制收入和急诊就诊后,COST-FACIT评分越高(经济负担越低)延迟推荐药物或手术的 odds 越低(OR 0.89,95%CI 0.87-0.92;P<.001)。
临床怎么用
- 在讨论预防性干预措施时应纳入经济毒性信息。
- 对肾结石患者评估经济毒性有助于识别延迟治疗风险较高者。
局限性
- 横断面设计无法确定经济毒性与治疗延迟之间的因果关系。
- 研究基于ResearchMatch志愿者样本,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess how financial toxicity may impact the risk of deferral of recommended therapy in nephrolithiasis patients. METHODS: We performed a nationwide cross-sectional survey of adult volunteers with kidney stone disease registered with ResearchMatch. Comprehensive Score for Financial Toxicity (COST-FACIT) score <21 was used to identify patients with nephrolithiasis-related financial toxicity. Coping mechanisms, dietary, and medical interventions for stone disease were compared between high/low financial toxicity groups. Multivariable logistic regression assessed characteristics associated with deferral of recommended medical or surgical interventions in the preceding year. RESULTS: Of 945 respondents with nephrolithiasis, 205 (21.6%) reported disease-related financial toxicity (COST ≤ 20). Individuals with financial toxicity were more likely to defer recommended medical (28.3% vs 3.8%; P <.001) or surgical therapy (22.4% vs 3.4%; P <.001) for stones in the preceding year and were more likely to cite cost concerns as barriers to following nutritional recommendations (Table 1). On multivariable analysis, after controlling for income and emergency presentation for stones, higher COST-FACIT score (lower financial burden) was associated with lower odds of deferring recommended medicines or surgery for stone disease (odds ratio [OR] 0.89, 95% confidence interval [CI] 0.87-0.92; P <.001). CONCLUSION: In this nationwide cross-sectional study, patients with kidney stones and associated financial toxicity were more likely to defer recommended surgical and medical therapy. Cost concerns were commonly cited reasons for not following medical, surgical, or dietary recommendations, highlighting a need to integrate this information into discussion of preventative interventions.
引用
- Cabo JJ, Kofman R, Ballantyne C, et al. Treatment Deferral and Coping Mechanisms Associated With Nephrolithiasis-related Financial Toxicity. Urology. 2025. PMID: 40602468. doi:10.1016/j.urology.2025.06.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。